Searchable News & Info From Reliable Online Sources.
Latest Real News From 140 News Sites Updated Every 15 Minutes.
- Psychedelic drug popular in 1960s could ease anxiety as doctors share warnings
A new study suggests that lysergic acid diethylamide (LSD), also known as acid, could reduce anxiety.This marks the first-ever trial to evaluate the safety and efficacy of MM120 (a pharmaceutical formulation of LSD) as a monotherapy for patients with moderate to severe generalized anxiety disorder, according to lead author Daniel Karlin, M.D., chief medical officer of MindMed, a biopharmaceutical company in New York.The study was published in the Journal of the American Medical Association.THE KEY TO LIVING LONGER COULD BE TIED TO A SURPRISING SUBSTANCE, STUDY SUGGESTSNearly 200 adults between the ages of 18 and 74 received either a single oral dose of LSD at various does, or a placebo "dummy pill," for a three-month period, according to a press release.The dosing sessions were individually conducted in private rooms with two trained monitors who observed the participants for at least 12 hours. No psychotherapy was provided.Researchers tracked changes in participants’ anxiety scores at… ...[TheTopNews] Read More.3 days ago - Home Chef and Gordon Ramsay Team Up to Bring 5-Star Flavors Home
Six-month partnership delivers exclusive, chef-crafted recipes inspired by Ramsay's signature dishes, bringing impressive meals to home kitchens ...[TheTopNews] Read More.3 days ago - Climate finance week at FAO aims to deliver climate solutions through agrifood systems
...[TheTopNews] Read More.3 days ago - Freight Market Showed Hopeful Signs in Q2
Mixed Signals in the Freight Market The U.S. freight industry showed signs of life in the second quarter of 2025, though experts caution that the road to full recovery remains uncertain. According to the U.S. Bank Freight Payment Index, both shipment volume and spending increased sequentially for the first time in three years. Shipment volume rose 2.4% compared to the first quarter, while spending ticked up 1.2%. Encouragingly, all five U.S. regions reported volume gains, with the Southwest leading at 6.7%. Bobby Holland, director of freight business analytics at U.S. Bank, called the growth “a welcome shift,” but emphasized that ongoing tariff volatility still clouds the outlook. Year-Over-Year Trends Still Weak While quarter-over-quarter improvements suggest stabilization, year-over-year comparisons were less favorable. National shipments dropped 9.8%, and spending declined 4.9%, though these figures marked the smallest annual decline since Q3 2023. ATA Chief Economist Bob Costello noted that while… ...[TheTopNews] Read More.3 days ago - ‘Next Ozempic’ aims to deliver 30% weight loss with fewer side effectsResearchers believe they may have the next, better version of Ozempic in the works.At Tufts University, scientists have developed a new drug that aims to boost weight loss while also reducing the nausea, muscle loss and weight regain associated with popular GLP-1 medications.The goal is for the "quadruple-action" medication to achieve long-lasting weight loss of up to 30% — matching the effectiveness of bariatric surgery, which reduces the size of the stomach, according to a study press release.COULD GLP-1 WEIGHT-LOSS MEDICATIONS LIKE OZEMPIC BECOME THE 'EVERYTHING DRUG'?Semaglutide medications, like Ozempic and Wegovy, mimic the natural hormone GLP‑1 (glucagon‑like peptide‑1), while tirzepatides (such as Mounjaro and Zepbound) target both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors.The new medication from Tufts targets a combination of four hormones — GLP-1, GIP, glucagon (the counterpart to insulin), and peptide YY, which reduces hunger, slows stomach emptying and may promote fat-burning."We built a single… ...[TheTopNews] Read More.3 days ago
« Previous
1
…
88
89
90
91
92
…
116
Next »
A new study suggests that lysergic acid diethylamide (LSD), also known as acid, could reduce anxiety.This marks the first-ever trial to evaluate the safety and efficacy of MM120 (a pharmaceutical formulation of LSD) as a monotherapy for patients with moderate to severe generalized anxiety disorder, according to lead author Daniel Karlin, M.D., chief medical officer of MindMed, a biopharmaceutical company in New York.The study was published in the Journal of the American Medical Association.THE KEY TO LIVING LONGER COULD BE TIED TO A SURPRISING SUBSTANCE, STUDY SUGGESTSNearly 200 adults between the ages of 18 and 74 received either a single oral dose of LSD at various does, or a placebo "dummy pill," for a three-month period, according to a press release.The dosing sessions were individually conducted in private rooms with two trained monitors who observed the participants for at least 12 hours. No psychotherapy was provided.Researchers tracked changes in participants’ anxiety scores at… ...[TheTopNews] Read More.
3 days ago
Six-month partnership delivers exclusive, chef-crafted recipes inspired by Ramsay's signature dishes, bringing impressive meals to home kitchens ...[TheTopNews] Read More.
3 days ago
...[TheTopNews] Read More.
3 days ago
Mixed Signals in the Freight Market The U.S. freight industry showed signs of life in the second quarter of 2025, though experts caution that the road to full recovery remains uncertain. According to the U.S. Bank Freight Payment Index, both shipment volume and spending increased sequentially for the first time in three years. Shipment volume rose 2.4% compared to the first quarter, while spending ticked up 1.2%. Encouragingly, all five U.S. regions reported volume gains, with the Southwest leading at 6.7%. Bobby Holland, director of freight business analytics at U.S. Bank, called the growth “a welcome shift,” but emphasized that ongoing tariff volatility still clouds the outlook. Year-Over-Year Trends Still Weak While quarter-over-quarter improvements suggest stabilization, year-over-year comparisons were less favorable. National shipments dropped 9.8%, and spending declined 4.9%, though these figures marked the smallest annual decline since Q3 2023. ATA Chief Economist Bob Costello noted that while… ...[TheTopNews] Read More.
3 days ago
Researchers believe they may have the next, better version of Ozempic in the works.At Tufts University, scientists have developed a new drug that aims to boost weight loss while also reducing the nausea, muscle loss and weight regain associated with popular GLP-1 medications.The goal is for the "quadruple-action" medication to achieve long-lasting weight loss of up to 30% — matching the effectiveness of bariatric surgery, which reduces the size of the stomach, according to a study press release.COULD GLP-1 WEIGHT-LOSS MEDICATIONS LIKE OZEMPIC BECOME THE 'EVERYTHING DRUG'?Semaglutide medications, like Ozempic and Wegovy, mimic the natural hormone GLP‑1 (glucagon‑like peptide‑1), while tirzepatides (such as Mounjaro and Zepbound) target both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors.The new medication from Tufts targets a combination of four hormones — GLP-1, GIP, glucagon (the counterpart to insulin), and peptide YY, which reduces hunger, slows stomach emptying and may promote fat-burning."We built a single… ...[TheTopNews] Read More.
3 days ago
The Searchable USWebDaily.com and TheTopNews NewsBank Helps You Be Better Informed, Faster! Spread The Word.
